Table 3. Change in functional status in study groups at 6 months.
FCM group (n = 35) | Non-FCM group (n = 30) | |||||
Baseline | 6-month follow-up | p value | Baseline | 6-month follow-up | p value | |
NYHA Class II | 43% (15/35) | 91% (32/35) | < 0.0001 | 63% (19/30) | 60% (18/30) | 1.000 |
NYHA Class III | 57% (20/35) | 9% (3/35) | 37% (11/30) | 40% (12/30) |
Results reported as % (n/N).
FCM, ferric carboxymaltose; NYHA, New York Heart Association.